Israeli therapeutics company Kamada files for a $69 million US IPO


Shutterstock photo

Kamada, which produces plasma-derived protein therapeutics, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. The company's shares are already listed on the Tel Aviv Stock Exchange under the symbol KMDA. The Ness Ziona, Israel-based company, which was founded in 1990 and booked $73 million in sales for the 12 months ended 12/31/2012, plans to list on the NASDAQ under the symbol KMDA. The company initially filed confidentially on 1/24/13. Morgan Stanley and Jefferies & Co. are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by